insights_auto
Why is 8NE up ၂.၄၄%?
Dive Deeperchevron_right
8NE:FRA
Lisata Therapeutics, Inc.
၀.၈၄ €
arrow_upward
+၂.၄၄%(+၀.၀၂၀) 1D
အောက် ၁၄, GMT+၂ ၂၂:၀၀:၀၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 8NE...
Open
၀.၈၄ €
High
၀.၈၄ €
Low
၀.၈၄ €
Mkt. cap
၁.၁၀ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၄.၃၄ €
52-wk low
၀.၇၄ €
No. of employees
၂၁
Open
၀.၈၄ €
High
၀.၈၄ €
Low
၀.၈၄ €
Mkt. cap
၁.၁၀ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၄.၃၄ €
52-wk low
၀.၇၄ €
No. of employees
၂၁
News stories
From web sources and news partners
TipRanks
·
ပြီးခဲ့သည့် ၇ နာရီ
Lisata Therapeutics Expands Board, Appoints Independent Director
Investing.com Canada
·
ပြီးခဲ့သည့် ၈ နာရီ
Lisata Therapeutics adds Jeffrey Farrow to board of directors By Investing.com
Stock Titan
·
ပြီးခဲ့သည့် ၈ နာရီ
A drug-company finance leader with more than 15 years in finance joins Lisata's board
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees၂၁
Founded၁၉၈၀
HeadquartersBasking Ridge, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitelisata.com